Core Viewpoint - Lisheng Pharmaceutical reported a mixed performance in its semi-annual earnings, with a decline in revenue but a significant increase in net profit and earnings per share [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 732 million yuan, representing a year-on-year decrease of 1.76% [2] - The net profit attributable to shareholders was around 343 million yuan, showing a substantial year-on-year increase of 235.04% [2] - Basic earnings per share reached 1.33 yuan, which is an increase of 232.5% compared to the previous year [2]

Core Viewpoint - Lisheng Pharmaceutical reported significant growth in revenue and net profit for the first half of 2025, driven by innovation and strategic investments [2][3]. Financial Performance - The company achieved a revenue of 732 million yuan and a net profit attributable to shareholders of 343 million yuan, marking a year-on-year increase of 235.04% [2]. - The basic earnings per share reached 1.33 yuan, up 232.50% from 0.40 yuan in the same period last year [2]. Strategic Initiatives - Lisheng Pharmaceutical plans to establish a 1 billion yuan equity investment fund in collaboration with Jianxin Equity to enhance business structure and operational strength [2]. - The company has identified over 300 quality merger and acquisition projects as part of its "14th Five-Year" strategic planning [3]. Research and Development - The company invested 60.51 million yuan in R&D, with an investment rate exceeding 8%, resulting in multiple breakthroughs [3]. - Lisheng Pharmaceutical applied for 9 patents and received approval for 3 core products during the first half of the year [3]. Marketing and Production - The company implemented a "four-wheel" marketing system, focusing on the core product Indapamide, which improved sales through a refined distribution network [4]. - Lisheng Pharmaceutical achieved a 100% compliance rate in drug market inspections and completed safety hazard rectifications [4]. Subsidiary Performance - Central Pharmaceutical integrated its marketing team, leading to a 14% increase in sales of Urokinase injection and significant growth in Heparin Sodium injection sales [5]. - The subsidiary San Yu Pharmacy ranked among the top retail pharmacies in Tianjin based on daily sales [5]. Governance and Efficiency - The company established a dynamic monitoring mechanism for loss-making enterprises and improved its ESG management system, achieving a six-year high in market value [6]. - Lisheng Pharmaceutical plans to increase R&D investments and expand its distribution network in the second half of the year [6].

Buyback and Shareholder Actions - Sinopec plans to repurchase A-shares with a total fund of no less than RMB 5 billion and no more than RMB 10 billion, potentially reducing its registered capital [1] - Hengbang Mining intends to reduce its stake in the Hong Kong-listed company, WanGuo Gold, by up to 40 million shares, representing approximately 3.69% of WanGuo's total share capital [5] Product Approvals and Market Launches - Wantai Biological's nine-valent HPV vaccine has received the batch release certificate, marking its official market launch and enhancing the company's product lineup [1] - Changchun High-tech's subsidiary has received acceptance for the clinical trial application of GenSci143, a dual-specific antibody drug, which may provide new treatment options for certain tumors [7] Financial Performance - Hongxin Electronics reported a 15.01% increase in revenue to RMB 3.494 billion and a 9.85% rise in net profit to RMB 53.99 million for the first half of 2025 [2] - Sanwei Xinan experienced a net loss of RMB 29.39 million in the first half of 2025, despite a 15.19% increase in revenue to RMB 195 million [3] Corporate Developments - TianTan Bio received a commitment from its controlling shareholder to resolve new competition issues arising from a recent acquisition [4] - Feilu Co. announced a potential change in control, leading to a temporary suspension of its stock trading [8] Investment and Expansion - Jinbei Electric's subsidiary has signed a purchase agreement for a factory in Europe, marking significant progress in establishing its European production base [1] - Shengshi Technology plans to establish a wholly-owned subsidiary to integrate AI and humanoid robot technology with innovative toy products, investing RMB 10 million [6]

（文章来源：证券日报） 证券日报网讯 8月21日晚间，力生制药发布公告称，公司第七届监事会第四十三次会议审议通过了《关 于2025年半年度报告全文及摘要的议案》等多项议案。 ...

智通财经APP讯，力生制药(002393.SZ)发布2025年半年度报告，该公司营业收入为7.32亿元，同比减少 1.76%。归属于上市公司股东的净利润为3.43亿元，同比增长235.04%。归属于上市公司股东的扣除非经 常性损益的净利润为1.04亿元，同比增长5.09%。基本每股收益为1.33元。 ...

2025年8月20日，天津 力生制药 股份有限公司（以下简称"力生制药"）发布关于2024年限制性股票激励 计划调整回购价格暨回购注销部分激励对象已获授但尚未解除限售的限制性股票事项的法律意见书。 部分限制性股票回购注销 因部分激励对象离职，根据《激励计划（草案）》相关规定，力生制药对其未解锁的限制性股票进行回 购注销。此次涉及首次授予的限制性股票数量为60,000股，回购价格为10.24元/股，回购款共计614,400 元，资金来源为公司自有资金。 已履行现阶段信息披露义务 激励计划调整回购价格 2025年4月22日，力生制药披露《2024年年度权益分派实施公告》，以2025年3月19日总股本257,704,999 股，扣除库存股1,439,980股后的256,265,019股为基数，向全体股东每10股派发现金股利3.50元人民币 （含税）。 鉴于权益分派方案实施完毕，根据相关规定，需对激励计划授予的激励股份（含预留部分）回购价格进 行调整。按照《激励计划（草案）》中派息调整公式，调整后的回购价格= 10.59 - 0.35 = 10.24元/股。 截至法律意见书出具日，力生制药已按要求履行现阶段必要的信息 ...

Core Viewpoint - The company reported a mixed performance in its 2025 semi-annual report, with a slight decline in revenue but a significant increase in net profit [1] Financial Performance - The company achieved an operating revenue of 732 million yuan in the first half of the year, representing a year-on-year decrease of 1.76% [1] - The net profit attributable to the parent company was 343 million yuan, showing a substantial year-on-year increase of 235.04% [1] - Basic earnings per share were reported at 1.33 yuan [1] Subsidiary Performance - The subsidiary, Biochemical Pharmaceutical, experienced strong performance through coordinated domestic and international trade efforts [1] - Sales revenue from injectable urokinase increased by 14% [1] - Domestic sales of heparin sodium injection grew by over 18%, while international sales surged by 48% year-on-year [1]

力生制药(002393.SZ)发布2025年半年度报告，上半年实现营业收入7.32亿元，同比下降1.76%；归属于 上市公司股东的净利润为3.43亿元，同比增长235.04%。 ...

证券代码：002393 证券简称：力生制药 公告编号：2025-052 天津力生制药股份有限公司 关于调整2024年限制性股票激励计划 回购价格暨回购注销部分激励对象已获授 但尚未解除限售的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"或"本公司"）于2025年8月20日召开 第七届董事会第五十二次会议和第七届监事会第四十三次会议，审议通过了《关于调整2024 年限制性股票激励计划回购价格暨回购注销部分激励对象已获授但尚未解除限售的限制性股 票的议案》。鉴于公司2024年度权益分派方案已实施完毕，根据《上市公司股权激励管理办 法》、公司《2024年限制性股票激励计划（草案）》及其摘要的相关规定及公司2025年第一 次临时股东大会的授权，董事会同意对2024年限制性股票激励计划授予的限制性股票（含预 留部分）的回购价格进行调整。限制性股票的回购价格由10.59元/股调整为10.24元/股。对首 批授予激励对象中1名因离职原因，不再符合激励条件的人员已获授但尚未解除限售的60,000 股限制性股票进行回 ...

证券代码：002393 证券简称：力生制药 公告编号：2025-051 天津力生制药股份有限公司 关于调整2022年限制性股票激励计划 回购价格暨回购注销部分激励对象已获授 但尚未解除限售的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"或"本公司"）于2025年8月20日召开 第七届董事会第五十二次会议和第七届监事会第四十三次会议，审议通过了《关于调整2022 年限制性股票激励计划回购价格暨回购注销部分激励对象已获授但尚未解除限售的限制性股 票的议案》。鉴于公司2024年度权益分派方案已实施完毕，根据《上市公司股权激励管理办 法》、公司《2022年限制性股票激励计划（草案）》及其摘要的相关规定及公司2022年第五 次临时股东大会的授权，董事会同意对2022年限制性股票激励计划授予的限制性股票（含预 留部分）回购价格进行调整。首次授予限制性股票的回购价格由9.11元/股调整为8.76元/股， 预留授予部分的回购价格由8.49元/股调整为8.14元/股。对首次授予激励对象中2名因离职及 退休原因，不再符 ...